.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Queensland Health
Cantor Fitzgerald
AstraZeneca
Merck
Cerilliant
Mallinckrodt
Chubb
Fuji
Julphar

Generated: June 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,537,982

« Back to Dashboard

Details for Patent: 6,537,982

Title: Method of treating prostatic diseases using active vitamin D analogues
Abstract:The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the prostate, e.g., prostatic cancer and prostatic hyperplasia, which includes administering to a patient in need thereof an active vitamin D analogue. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.
Inventor(s): Bishop; Charles W. (Madison, WI), Knutson; Joyce C. (Madison, WI), Mazess; Richard B. (Madison, WI)
Assignee: Bone Care International, Inc. (Middleton, WI)
Filing Date:Feb 23, 1998
Application Number:09/596,149
Claims:1. A pharmaceutical combination comprising a first anticancer agent which is an active vitamin D compound; and (b) a second anticancer agent, wherein the active vitamin D compound is a 1.alpha.-hydroxyvitamin D compound having a hydrocarbon moiety substituted at C-24.

2. A pharmaceutical combination comprising a first anticancer agent which is an active vitamin D compound; and (b) a second anticancer agent, wherein the active vitamin D compound is 1.alpha.,24-dihydroxyvitamin D.sub.2, 1.alpha.,24-dihydroxyvitamin D.sub.4, 1.alpha.,25-dihydroxyvitamin D.sub.2, 1.alpha.,25-dihydroxyvitamin D.sub.4, 1.alpha.-hydroxyvitamin D.sub.2 or 1.alpha.-hydroxyvitamin D.sub.4.

3. The pharmaceutical combination of claim 1, wherein the first anticancer agent and the second anticancer agent are co-administered.

4. The pharmaceutical combination of claim 1, wherein the second anticancer agent is selected from the group consisting of estramustine phosphate, prednimustine, cisplatin, 5-fluoro-uracil, melphalan, hydroxyurea, mitomycin, idarubicin, methotrexate, adriamycin and daunomycin.

5. The pharmaceutical combination of claim 3, wherein the second anticancer agent is selected from the group consisting of estramustine phosphate, prednimustine, cisplatin, 5-fluoro-uracil, melphalan, hydroxyurea, mitomycin, idarubicin, methotrexate, adriamycin and daunomycin.

6. The pharmaceutical combination of claim 2, wherein the first anticancer agent and the second anticancer agent are co-administered.

7. The pharmaceutical combination of claim 2, wherein the second anticancer agent is selected from the group consisting of estramustine phosphate, prednimustine, cisplatin, 5-fluoro-uracil, melphalan, hydroxyurea, mitomycin, idarubicin, methotrexate, adriamycin and daunomycin.

8. The pharmaceutical combination of claim 6, wherein the second anticancer agent is selected from the group consisting of estramustine phosphate, prednimustine, cisplatin, 5-fluoro-uracil, melphalan, hydroxyurea, mitomycin, idarubicin, methotrexate, adriamycin and daunomycin.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Queensland Health
McKesson
McKinsey
Accenture
Johnson and Johnson
Chinese Patent Office
Merck
Citi
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot